Xeris Pharmaceuticals Inc Annual Revenue Report

Jeremy Jul 21, 2026

Xeris Pharmaceuticals, a pioneering biopharmaceutical company, has been making significant strides in the industry with its innovative therapeutic approaches. A key metric to gauge the company's progress and success is its annual revenue, a figure that reflects the impact of its products and pipeline on the market.

the top pharma companies in 2012 infographicly shows what they are doing
the top pharma companies in 2012 infographicly shows what they are doing

As of the company's latest financial filings, Xeris Pharmaceuticals has reported annual revenues that have seen a steady growth trajectory, driven by the commercial success of its approved products, such as Gvoke (for the treatment of insulin relacionados hypoglycemia), and its robust pipeline fueled by partnerships and licensing deals.

the top 10 pharmacultical markets in us dollars info graphic by mark strick
the top 10 pharmacultical markets in us dollars info graphic by mark strick

Xeris Pharmaceuticals' Annual Revenue Trends

To understand Xeris Pharmaceuticals' annual revenue performance, let's delve into the trends observed over the years. The company has transitioned from a pre-revenue state to a notable player in the life science sector, with annual revenues exceeding $100 million.

the top pharmacy companies by market cap
the top pharmacy companies by market cap

The trajectory, while influenced by market dynamics and the broader industry landscape, also mirrors Xeris' strategic focus on developing and commercializing ready-to-use liquidproducts and advancing its pipeline.

Key Milestones in Revenue Growth

Money Morning — Stock News & Market Analysis
Money Morning — Stock News & Market Analysis

In late 2019, Xeris Pharmaceuticals achieved its first commercial revenue with the launch of Gvoke in the US. This marked the start of the company's top-line growth and prompted an increased focus on driving market penetration and expanding into new geographies.

A significant revenue milestone was reached in 2021, when the company's annual revenues crossed the $100 million threshold, a testament to the success of its commercial strategy and the promise of its pipeline.

Gvoke: The Revenue Driver

Big Pharma Companies, Pharmacy Business Investment Insights, Investing Strategies For Pharmaceutical Stocks, Pharmaceutical Companies Patent Chart, Investing In Pharmaceutical Stocks, Pharmaceutical Company, Pharmaceutical Industry Analysis, Investing Strategies For Allergan Stock, Investor Analysis Of Vitrox Stock
Big Pharma Companies, Pharmacy Business Investment Insights, Investing Strategies For Pharmaceutical Stocks, Pharmaceutical Companies Patent Chart, Investing In Pharmaceutical Stocks, Pharmaceutical Company, Pharmaceutical Industry Analysis, Investing Strategies For Allergan Stock, Investor Analysis Of Vitrox Stock

Gvoke, a ready-to-use liquid glucagon, has been the primary revenue generator for Xeris Pharmaceuticals. The product's unique formulation and delivery system offer a convenient alternative to traditional glucagon emergency treatments, driving its adoption and market share.

The product's performance is reflected in the company's financials, with Gvoke contributing substantially to its annual revenues. As the product continues to gain traction, it is expected to maintain its status as a key revenue driver for Xeris Pharmaceuticals.

Factors Influencing Xeris Pharmaceuticals' Annual Revenue

. Periodic Table
. Periodic Table

The annual revenue of Xeris Pharmaceuticals can be attributed to a combination of factors, including the success of its marketed products, strategic partnerships, and progress in its pipeline.

Understanding these factors can provide valuable insights into the company's revenue projection and growth potential.

4 Easy Strategies to Increase Clinical Revenue for Independent Pharmacies
4 Easy Strategies to Increase Clinical Revenue for Independent Pharmacies
Pfizer | ఫైజర్ | फाइजर  Pfizer Inc. is an American multinational pharmaceutical and biotechnology co
Pfizer | ఫైజర్ | फाइजर Pfizer Inc. is an American multinational pharmaceutical and biotechnology co
𝐓𝐡𝐞 𝐭𝐨𝐩 10 𝐩𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐛𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 𝐜𝐚𝐩
𝐓𝐡𝐞 𝐭𝐨𝐩 10 𝐩𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐛𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 𝐜𝐚𝐩
https://brazilsfe.blogspot.com/2026/05/2025-Pharm-Exec-Top-50-Companies-As-50-Principais-Empresas-da-Pharm-Exec.html
2025 | As Top 50 Principais Empresas da Indústria Farmacêutica
✔ Brazil SFE®

#BrazilSFE #IndústriaFarmacêutica #Top50 #Pharma #PharmaCompanies #GSK #Grifols #HuadongMedicine #Incyte #Ipsen #JazzPharmaceuticals #JiangsuHengruiPharmaceuticals #MerckKGaA #Moderna #Novartis #Organon #OtsukaHoldings #RegeneronPharmaceuticals #SandozGroup #Sanofi #SinoBiopharmaceutical #STADArzneimi... Top 50, Pharma Companies
https://brazilsfe.blogspot.com/2026/05/2025-Pharm-Exec-Top-50-Companies-As-50-Principais-Empresas-da-Pharm-Exec.html 2025 | As Top 50 Principais Empresas da Indústria Farmacêutica ✔ Brazil SFE® #BrazilSFE #IndústriaFarmacêutica #Top50 #Pharma #PharmaCompanies #GSK #Grifols #HuadongMedicine #Incyte #Ipsen #JazzPharmaceuticals #JiangsuHengruiPharmaceuticals #MerckKGaA #Moderna #Novartis #Organon #OtsukaHoldings #RegeneronPharmaceuticals #SandozGroup #Sanofi #SinoBiopharmaceutical #STADArzneimi... Top 50, Pharma Companies
the top 20 big pharma companies in asia are on this page, and there is
the top 20 big pharma companies in asia are on this page, and there is
Non-PBM Revenue Streams Pharmacies Are Winning With in 2026
Non-PBM Revenue Streams Pharmacies Are Winning With in 2026
Maximizing Pharmacy Cash Revenue: 2024’s Best Insights
Maximizing Pharmacy Cash Revenue: 2024’s Best Insights
The production and quality requirements of #pharmaceutical companies
The production and quality requirements of #pharmaceutical companies
Study Pharmaceutical Engineering in Australia
Study Pharmaceutical Engineering in Australia
Looking for ways to increase your pharmacy's profitability?
Looking for ways to increase your pharmacy's profitability?
Ferring Pharmaceuticals bolsters global gene therapy supply chain Ffrench Pharmaceuticals Logo, Pfizer Company Logo, Gene Therapy, Supply Chain, Instagram
Ferring Pharmaceuticals bolsters global gene therapy supply chain Ffrench Pharmaceuticals Logo, Pfizer Company Logo, Gene Therapy, Supply Chain, Instagram
Maximize Your Pharmacy's Profitability with These 7 Key Strategies
Maximize Your Pharmacy's Profitability with These 7 Key Strategies
Most Valuable Pharma Brands (2024)
Most Valuable Pharma Brands (2024)
Pharmacy Revenue | Why Should Pharmacy Owners Care About ACOs?
Pharmacy Revenue | Why Should Pharmacy Owners Care About ACOs?
Top 5 Pharma Stocks
Top 5 Pharma Stocks
Aprepitant Injection Market Size, Share & Revenue Outlook 2032
Aprepitant Injection Market Size, Share & Revenue Outlook 2032
Weight Loss Program For New Years | Increasing Pharmacy Revenue
Weight Loss Program For New Years | Increasing Pharmacy Revenue
The European Union's top 5 pharmaceutical trading partners - EU exports 2012 Pharmaceutical Industry Study, Pharmaceutical Supply Chain Diagram, Pharmaceutical Excipients Chart, Historical Pharmaceutical Research, Pharmaceutical Companies Patent Chart, European Union History Infographic, Pharmaceutical Patent Trends, Eu Agricultural Trade Infographic, Export And Import Statistics Map
The European Union's top 5 pharmaceutical trading partners - EU exports 2012 Pharmaceutical Industry Study, Pharmaceutical Supply Chain Diagram, Pharmaceutical Excipients Chart, Historical Pharmaceutical Research, Pharmaceutical Companies Patent Chart, European Union History Infographic, Pharmaceutical Patent Trends, Eu Agricultural Trade Infographic, Export And Import Statistics Map
shelves in a pharmacy store filled with medicines
shelves in a pharmacy store filled with medicines
the role of pharmic - benefit managers in pharmacy infographical design and development
the role of pharmic - benefit managers in pharmacy infographical design and development

Commercial Success of Marketed Products

The commercial performance of Xeris Pharmaceuticals' approved products, such as Gvoke, significantly contributes to its annual revenue. The demand for these products, influenced by their clinical utility and competitive positioning, has a direct impact on the company's top line.

Additionally, efforts to expand the market reach of these products through strategic partnerships and geographic expansion further enhance their sales performance and overall revenue contribution.

Pipeline Progress and Potential Blockbusters

Xeris Pharmaceuticals' pipeline, rich with ready-to-use liquid products and innovative therapies, carries significant potential for driving future growth. The progress of late-stage pipeline assets, like its ready-to-use liquid semaglutide (GLP-1 receptor agonist) for type 2 diabetes, can considerably influence the company's annual revenue.

Success in these assets' development and commercialization could translate into substantial revenue contributions, potentially transforming Xeris Pharmaceuticals into a multi-product biopharmaceutical company.

As Xeris Pharmaceuticals continues to build on its current momentum, with a robust pipeline and a strategic focus on developing and commercializing innovative products, investors and industry observers eagerly await the company's next phase of growth. With its sights set on becoming a leading player in the biopharmaceutical sector, the company's annual revenue serves as a promising indicator of its progress towards this strategic goal.